Holen Sie sich die Stockscreener-App
66.03
0.50%
-0.33
Handel nachbörslich:
66.26
0.23
+0.35%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt DXCM?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$66.36
Offen:
$66.77
24-Stunden-Volumen:
3.70M
Relative Volume:
0.81
Marktkapitalisierung:
$25.89B
Einnahmen:
$4.30B
Nettoeinkommen (Verlust:
$571.50M
KGV:
46.22
EPS:
1.4285
Netto-Cashflow:
$570.80M
1W Leistung:
-1.87%
1M Leistung:
-17.99%
6M Leistung:
+7.14%
1J Leistung:
-3.77%
1-Tages-Spanne:
$65.88
$67.43
1-Wochen-Bereich:
$63.53
$68.00
52-Wochen-Spanne:
$57.52
$93.25
Dexcom Inc Stock (DXCM) Company Profile
Firmenname
Dexcom Inc
Sektor
Branche
Telefon
(858) 200-0200
Adresse
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Vergleichen Sie DXCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
66.03 | 26.02B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
133.02 | 232.77B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.90 | 143.29B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
369.24 | 140.03B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
98.33 | 126.25B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
76.72 | 44.95B | 5.69B | 1.41B | 577.90M | 6.9828 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Eingeleitet | Argus | Buy |
| 2025-06-16 | Eingeleitet | Truist | Buy |
| 2025-05-30 | Eingeleitet | Goldman | Buy |
| 2025-04-10 | Eingeleitet | Mizuho | Outperform |
| 2025-02-03 | Hochstufung | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Eingeleitet | Redburn Atlantic | Neutral |
| 2024-03-12 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Eingeleitet | UBS | Buy |
| 2023-01-26 | Eingeleitet | Wolfe Research | Outperform |
| 2022-10-18 | Eingeleitet | Barclays | Equal Weight |
| 2022-10-12 | Eingeleitet | Jefferies | Buy |
| 2022-07-15 | Eingeleitet | Bernstein | Outperform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Buy |
| 2022-02-03 | Hochstufung | BTIG Research | Neutral → Buy |
| 2022-01-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2021-10-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-07-21 | Fortgesetzt | Cowen | Outperform |
| 2021-05-28 | Hochstufung | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Eingeleitet | Barclays | Overweight |
| 2021-04-15 | Eingeleitet | Atlantic Equities | Overweight |
| 2021-01-06 | Hochstufung | UBS | Neutral → Buy |
| 2020-10-02 | Herabstufung | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Bestätigt | Piper Sandler | Overweight |
| 2020-05-14 | Eingeleitet | Wells Fargo | Equal Weight |
| 2020-03-05 | Eingeleitet | Citigroup | Buy |
| 2019-11-07 | Bestätigt | Canaccord Genuity | Buy |
| 2019-11-07 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-10-23 | Eingeleitet | Stifel | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-10-19 | Hochstufung | Goldman | Sell → Neutral |
| 2018-09-12 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Bestätigt | Canaccord Genuity | Buy |
| 2018-07-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
| 2018-05-03 | Bestätigt | Canaccord Genuity | Buy |
| 2018-04-04 | Eingeleitet | Goldman | Sell |
| 2018-04-04 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-23 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Bestätigt | Wedbush | Outperform |
Alle ansehen
Dexcom Inc Aktie (DXCM) Neueste Nachrichten
What analysts say about DexCom Inc DC4 stockSector Performance Drivers & Diversify Intelligently to Avoid Big Hits - earlytimes.in
Applying big data sentiment scoring on DexCom Inc.Trend Reversal & Entry and Exit Point Strategies - newser.com
Can DexCom Inc. (DC4) stock deliver consistent EPS growthWeekly Trend Summary & Low Risk Entry Point Guides - newser.com
DexCom May Be The Most Underrated Growth Story In Healthcare (NASDAQ:DXCM) - Seeking Alpha
What dividend safety rating applies to DexCom Inc. (DC4) stockEarnings Overview Report & AI Forecasted Entry and Exit Points - newser.com
Combining price and volume data for DexCom Inc.July 2025 Fed Impact & Daily Growth Stock Tips - newser.com
Can DexCom Inc. stock deliver sustainable ROEM&A Rumor & Verified Swing Trading Watchlists - newser.com
DexCom, Inc. Reports Second Quarter 2017 Financial Results - ADVFN
Is DexCom Inc. (DC4) stock resilient in recession scenariosPortfolio Risk Summary & Technical Pattern Alert System - newser.com
Published on: 2025-10-05 05:15:42 - newser.com
Is DexCom Inc. stock entering bullish territoryWeekly Loss Report & Free Weekly Chart Analysis and Trade Guides - newser.com
Can DexCom Inc. (DC4) stock sustain double digit ROE2025 Technical Overview & Low Volatility Stock Recommendations - newser.com
Why Analysts See DexCom’s Outlook Shifting Amid New Leadership and Changing Growth Drivers - Yahoo Finance
DexCom Stock Price, Quotes and Forecasts | NASDAQ:DXCM - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of DexCom, Inc.DXCM - WV News
What MACD trends signal for DexCom Inc. (DC4) stockBreakout Watch & Free Risk Controlled Daily Trade Plans - newser.com
How to escape a deep drawdown in DexCom Inc.Quarterly Profit Report & AI Powered Market Entry Ideas - newser.com
Dexcom Schedules Third Quarter 2025 Earnings Release and Conference Call for October 30, 2025 at 4:30 p.m. Eastern Time. - BioSpace
Why DexCom Inc. stock remains on watchlistsBond Market & Real-Time Stock Movement Alerts - newser.com
North America Precision Nutrition Market Analysis Report 2025-2032: Abbott, Dexcom, Nestle and DSM Lead Ecosystem Expansion with Integrated Diagnostics and Supplements - Yahoo Finance
DexCom (NASDAQ:DXCM) Given New $89.00 Price Target at The Goldman Sachs Group - Defense World
DexCom (NASDAQ:DXCM) Trading Down 4.9% on Analyst Downgrade - Defense World
Goldman Sachs Maintains DexCom (DXCM) Buy Recommendation - Nasdaq
TD Cowen Maintains its Buy Rating and $100 PT for DexCom, Inc. (DXCM) - Insider Monkey
DEXCOM SHAREHOLDER ALERT: Kaskela Law LLC Announces - GlobeNewswire
DexCom, Inc. (DXCM) Showcases Next-Gen CGM Features at EASD 2025 - Insider Monkey
Goldman Sachs Adjusts Price Target on DexCom to $89 From $104, Maintains Buy Rating - MarketScreener
Published on: 2025-10-01 04:25:09 - newser.com
TD Private Client Wealth LLC Lowers Stock Holdings in DexCom, Inc. $DXCM - Defense World
DexCom, Inc. $DXCM Shares Acquired by Farther Finance Advisors LLC - Defense World
DexCom’s (DXCM) “Buy” Rating Reaffirmed at Canaccord Genuity Group - Defense World
DexCom (DXCM) Maintains Buy Rating with Price Target Unchanged a - GuruFocus
DexCom (NASDAQ:DXCM) Earns Buy Rating from Canaccord Genuity Group - MarketBeat
Will Rising Costs Hurt Garodia Chemicals Limiteds Margins This YearEarnings Per Share Trends & Free Long-Term Investment Planning - earlytimes.in
Finanzdaten der Dexcom Inc-Aktie (DXCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.75%
0.38%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):